General Information of Drug (ID: DMCO8UZ)

Drug Name
KP-496 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
PubChem CID
11578433
TTD Drug ID
DMCO8UZ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Modulator [1]
Thromboxane A2 receptor (TBXA2R) TT2O84V TA2R_HUMAN Modulator [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Leukotriene CysLT1 receptor (CYSLTR1) DTT CYSLTR1 3.233 3.733 -0.152 3.797
Thromboxane A2 receptor (TBXA2R) DTT TBXA2R 6.075 5.925 6.729 6.096
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Leukotriene CysLT1 receptor (CYSLTR1) DTT CYSLTR1 1.96E-02 0.24 0.43
Thromboxane A2 receptor (TBXA2R) DTT TBXA2R 2.78E-04 -0.11 -0.31
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.